GO:1902613 negative regulation of anti-Mullerian hormone signaling pathway: Ovarian Folliculogenesis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902613 describes any process that stops, prevents, or reduces the frequency, rate, or extent of anti-Mullerian hormone (AMH) signaling.
• AMH signals through the type 2 AMH receptor (AMHR2), a serine/threonine kinase receptor that is itself subject to dominant-negative splice variants capable of inhibiting the pathway.
• Negative regulation of AMH signaling is critical in ovarian folliculogenesis, where AMH restrains primordial follicle recruitment and modulates follicle sensitivity to FSH.
• In the ovary, AMH signaling involves stromal fibroblasts as well as granulosa cells, revealing a paracrine network that can be disrupted in disease.
• Attenuated AMH signaling is implicated in ovarian hyperstimulation syndrome (OHSS) and in cadmium-induced granulosa cell damage, where AMH negatively regulates stem cell factor.
• AMH signaling also operates beyond the gonad, for example by negatively regulating osteoclast differentiation via suppression of RANKL, and has been linked to male bias in autism.
Description
Anti-Mullerian hormone (AMH), also known as Mullerian-inhibiting substance, is a member of the TGF-beta superfamily that plays a central role in reproductive development and ovarian physiology. The signaling pathway triggered by AMH is tightly controlled, and its negative regulation is essential for normal folliculogenesis, gonadal function, and tissue homeostasis. GO:1902613, negative regulation of anti-Mullerian hormone signaling pathway, captures the biological processes that attenuate or terminate AMH signal transduction. Understanding this term is important because dysregulated AMH signaling contributes to reproductive disorders such as ovarian hyperstimulation syndrome and to broader pathologies including bone metabolism and neurodevelopmental conditions. Researchers studying fertility, endocrinology, and TGF-beta signaling need precise tools to dissect how AMH signaling is switched off, and CRISPR-based models offer a direct route to test causal roles of candidate regulators.
negative regulation of anti-Mullerian hormone signaling pathway At A Glance
| GO ID | GO:1902613 |
|---|---|
| GO term | negative regulation of anti-Mullerian hormone signaling pathway |
| Ontology | biological_process |
| Synonym | down regulation of anti-Mullerian hormone signaling pathway; down-regulation of anti-Mullerian hormone signaling pathway; downregulation of anti-Mullerian hormone signaling pathway; inhibition of anti-Mullerian hormone signaling pathway |
| Major function | Attenuation or termination of AMH signal transduction, thereby modulating follicle recruitment, granulosa cell function, and AMH-responsive target tissues |
| Key ligand | Anti-Mullerian hormone (AMH), a TGF-beta superfamily member |
| Key receptor | AMH type 2 receptor (AMHR2), a serine/threonine kinase receptor with dominant-negative splice variants |
| Related processes | Ovarian folliculogenesis, granulosa cell differentiation, osteoclast differentiation, and neurodevelopmental sex bias |
| Disease relevance | Ovarian hyperstimulation syndrome, cadmium-induced granulosa cell damage, and autism spectrum disorder |
What Is GO:1902613?
GO:1902613 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the anti-Mullerian hormone signaling pathway. In practical terms, it encompasses molecular events such as receptor downregulation, expression of dominant-negative receptor isoforms, sequestration of ligand, and intracellular feedback that collectively dampen AMH signal transduction. This negative regulation ensures that AMH signaling is not constitutively active, allowing dynamic control of follicle recruitment and other AMH-dependent processes.
Why Is negative regulation of anti-Mullerian hormone signaling pathway Important in Cell Biology?
Negative regulation of AMH signaling is important because AMH is a key gatekeeper of primordial follicle recruitment and ovarian reserve, and its signaling must be precisely tuned to avoid premature follicle depletion or excessive inhibition. Disruption of this negative regulation can lead to reproductive disorders such as ovarian hyperstimulation syndrome, where attenuated AMH signaling has been implicated in pathogenesis. Beyond the ovary, AMH signaling influences osteoclast differentiation and bone metabolism, and has been associated with neurodevelopmental traits such as male bias in autism. Thus, understanding GO:1902613 provides mechanistic insight into fertility, bone health, and neurodevelopment, and offers targets for therapeutic intervention.
• Controls ovarian reserve by modulating AMH-mediated inhibition of primordial follicle recruitment.
• Involves dominant-negative AMHR2 splice variants that can inhibit AMH signaling.
• Dysregulation is linked to ovarian hyperstimulation syndrome (OHSS).
• AMH negatively regulates stem cell factor in cadmium-induced granulosa cell damage.
• AMH signaling in the ovary involves stromal fibroblasts, expanding the cellular players in negative regulation.
• AMH negatively regulates osteoclast differentiation by suppressing RANKL, linking the pathway to bone biology.
• Altered AMH signaling may contribute to male bias in autism.
• Provides a model for studying TGF-beta superfamily feedback mechanisms.
• Offers CRISPR targets for fertility preservation and reproductive medicine.
• Enables dissection of paracrine and autocrine loops in gonadal and non-gonadal tissues.
What Happens During negative regulation of anti-Mullerian hormone signaling pathway?
Ligand availability and sequestration
In simple terms: The amount of AMH available to bind its receptor can be reduced, which turns down the signal.
Negative regulation of AMH signaling can occur at the level of ligand availability. AMH is produced by granulosa cells and acts in a paracrine manner to inhibit primordial follicle recruitment. Changes in AMH expression or sequestration can reduce the frequency or extent of receptor activation, thereby contributing to negative regulation of the pathway. In the ovary, stromal fibroblasts participate in AMH signaling, suggesting that ligand presentation or sequestration may involve multiple cell types.
Receptor inhibition by dominant-negative isoforms
In simple terms: Some forms of the AMH receptor can block the normal receptor from working.
The type 2 AMH receptor (AMHR2) has splice variants that act as dominant-negative inhibitors of AMH signaling. These variants can interfere with functional receptor complexes, reducing the frequency, rate, or extent of AMH signal transduction. This represents a direct molecular mechanism for negative regulation of the pathway.
Intracellular feedback and downstream suppression
In simple terms: Inside the cell, feedback loops can shut down the signal after it starts.
AMH signals through AMHR2 and downstream SMAD effectors, and negative regulation can occur via intracellular feedback that suppresses these downstream events. For example, AMH negatively regulates stem cell factor in granulosa cells, indicating that AMH signaling itself can trigger suppressive cascades that limit its own output. Such feedback ensures that AMH signaling is transient and context-dependent.
Cross-talk with other signaling pathways
In simple terms: Other signals can interfere with AMH signaling to turn it down.
Negative regulation of AMH signaling can be influenced by cross-talk with other pathways. In osteoclasts, AMH negatively regulates differentiation by suppressing the RANKL pathway, showing that AMH signaling intersects with NF-kB signaling to modulate cell fate. In the ovary, AMH signaling involves stromal fibroblasts, suggesting paracrine cross-talk that can attenuate AMH action. These interactions provide additional layers of negative regulation.
Pathophysiological attenuation in disease
In simple terms: In some diseases, the AMH signal is weakened, which contributes to the condition.
Attenuated AMH signaling plays an important role in the pathogenesis of ovarian hyperstimulation syndrome, where reduced AMH pathway activity is observed. Similarly, AMH participates in cadmium-induced granulosa cell damage by negatively regulating stem cell factor, linking environmental exposure to altered AMH signaling. These examples illustrate how negative regulation of AMH signaling can be maladaptive in disease contexts.
Key Genes Involved in GO:1902613 negative regulation of anti-Mullerian hormone signaling pathway
The following genes and proteins are central to AMH signaling and its negative regulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AMH | Ligand that activates AMH signaling; inhibits primordial follicle recruitment | Target for modulating ovarian reserve and fertility |
| AMHR2 | Type 2 AMH receptor; mediates signal transduction; splice variants act as dominant-negative inhibitors | Key node for negative regulation via dominant-negative isoforms |
| SMAD1/5/8 | Downstream effectors of AMH signaling | Readouts of pathway activity and feedback |
| FSHR | FSH receptor; AMH modulates follicle sensitivity to FSH | Context for AMH negative regulation in folliculogenesis |
| KITLG | Stem cell factor; negatively regulated by AMH in granulosa cells | Marker of AMH-mediated negative regulation in cadmium toxicity |
| RANKL | Receptor activator of NF-kB ligand; suppressed by AMH in osteoclasts | Link between AMH signaling and bone metabolism |
| NFKB1 | NF-kB subunit involved in RANKL pathway | Mediator of AMH effects on osteoclast differentiation |
| CYP19A1 | Aromatase; granulosa cell function marker | Indicator of granulosa cell state in AMH signaling studies |
| INHBA | Inhibin subunit; TGF-beta superfamily member | Comparator for AMH signaling in follicle development |
| INHBB | Inhibin subunit; TGF-beta superfamily member | Comparator for AMH signaling in follicle development |
| GDF9 | Oocyte-derived growth factor; regulates folliculogenesis | Context for AMH signaling in follicle development |
| BMP15 | Oocyte-derived growth factor; regulates folliculogenesis | Context for AMH signaling in follicle development |
| CDKN1B | Cell cycle inhibitor; potential downstream of AMH | Marker of granulosa cell quiescence |
| FOXL2 | Granulosa cell transcription factor | Marker of granulosa cell identity in AMH studies |
| WT1 | Stromal fibroblast marker | Marker of ovarian stroma in AMH signaling |
| COL1A1 | Fibroblast marker | Marker of stromal contribution to AMH signaling |
| ACVR1 | Type 1 receptor for TGF-beta superfamily | Potential mediator of AMH signaling |
| BMPR2 | Type 2 receptor for BMPs | Comparator for AMHR2 in TGF-beta signaling |
How Is negative regulation of anti-Mullerian hormone signaling pathway Regulated?
Negative regulation of AMH signaling is itself regulated at multiple levels. Dominant-negative AMHR2 splice variants provide a direct inhibitory mechanism. In the ovary, AMH signaling involves stromal fibroblasts, indicating that paracrine factors from the stroma can modulate AMH action. AMH negatively regulates stem cell factor in granulosa cells, suggesting an autocrine feedback loop. Additionally, AMH suppresses RANKL in osteoclasts, showing cross-regulation with NF-kB signaling. These mechanisms collectively tune the frequency, rate, and extent of AMH signaling in different tissues.
negative regulation of anti-Mullerian hormone signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AMH | Ovarian hyperstimulation syndrome | AMH knockout or overexpression in granulosa cell lines |
| AMHR2 | Disrupted AMH signaling | Knock-in of dominant-negative AMHR2 splice variants |
| KITLG | Cadmium-induced granulosa cell damage | KITLG reporter or knockout in granulosa cells |
| RANKL | Osteoclast differentiation and bone metabolism | RANKL promoter reporter in osteoclast precursors |
| AMH | Male bias in autism | AMH overexpression in neurodevelopmental models |
Ovarian hyperstimulation syndrome (OHSS)
Attenuated AMH signaling pathway plays an important role in the pathogenesis of ovarian hyperstimulation syndrome. Reduced AMH pathway activity may contribute to excessive follicle recruitment and ovarian enlargement characteristic of OHSS. Understanding negative regulation of AMH signaling could inform strategies to prevent or manage OHSS.
Cadmium-induced granulosa cell damage
AMH participates in ovarian granulosa cell damage due to cadmium exposure by negatively regulating stem cell factor. This suggests that environmental toxicants can disrupt AMH signaling and its negative regulation, leading to granulosa cell dysfunction. The KITLG/SCF axis is a downstream target of AMH in this context.
Bone metabolism and osteoclast differentiation
AMH negatively regulates osteoclast differentiation by suppressing the receptor activator of nuclear factor-kB ligand pathway. This links AMH signaling to bone homeostasis and suggests that negative regulation of AMH signaling may influence osteoporosis or other bone disorders. The RANKL/NF-kB axis is a key mediator.
Autism spectrum disorder and neurodevelopment
Inhibin B and anti-Mullerian hormone/Mullerian-inhibiting substance may contribute to the male bias in autism. This hypothesis links AMH signaling to neurodevelopmental sex differences, although the mechanisms remain under investigation. Negative regulation of AMH signaling could modulate this effect.
From negative regulation of anti-Mullerian hormone signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of AMHR2 increase AMH signaling? | AMHR2 knockout cell model |
| Do dominant-negative AMHR2 variants inhibit AMH signaling? | Point mutation or knock-in of AMHR2 splice variants |
| How does AMH regulate KITLG expression? | KITLG tagged knock-in or reporter |
| Does AMH suppress RANKL in osteoclasts? | RANKL overexpression or knockout in osteoclast precursors |
| What is the role of stromal fibroblasts in AMH signaling? | Co-culture with WT1+ stromal fibroblasts |
| Can AMH signaling be modulated in OHSS? | AMH overexpression in granulosa cell models |
How to Study the negative regulation of anti-Mullerian hormone signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome changes | Identify AMH-regulated genes |
| Western blot | Protein levels and phosphorylation | Assess SMAD activation |
| Luciferase reporter | Promoter activity | Quantify KITLG or RANKL suppression |
| Co-immunoprecipitation | Protein interactions | Detect AMHR2 complexes |
| Immunofluorescence | Protein localization | Map AMH signaling in ovarian tissue |
| ELISA | AMH or inhibin levels | Measure ligand availability |
| CRISPR screen | Gene function | Identify negative regulators of AMH signaling |
| Flow cytometry | Cell surface markers | Sort granulosa or stromal cells |
Transcriptomic profiling of AMH-responsive genes
RNA-seq can be used to identify genes whose expression changes upon modulation of AMH signaling, such as KITLG and RANKL. This approach helps define the downstream transcriptional network of negative regulation.
Protein-protein interaction and signaling assays
Co-immunoprecipitation and Western blotting can detect AMHR2 complexes and SMAD phosphorylation to assess pathway activity. These methods are useful for testing dominant-negative receptor variants.
Reporter assays for pathway activity
Luciferase reporters driven by AMH-responsive promoters (e.g., KITLG or RANKL) can quantify negative regulation in live cells. This enables high-throughput screening of regulators.
Imaging of ovarian follicles and stroma
Immunofluorescence and in situ hybridization can localize AMH, AMHR2, and stromal markers in ovarian tissue. This reveals spatial aspects of negative regulation.
How CRISPR Can Be Used to Study GO:1902613 negative regulation of anti-Mullerian hormone signaling pathway
Knockout
CRISPR knockout of AMHR2 or downstream effectors can be used to abolish AMH signaling and study compensatory negative regulation. Knockout of KITLG or RANKL can test their roles as downstream targets. These models help determine whether a candidate gene is required for negative regulation of AMH signaling.
Point Mutation
Point mutations can be introduced into AMHR2 to mimic dominant-negative splice variants or to disrupt kinase activity. Such models allow precise dissection of receptor domains required for negative regulation. They are also useful for studying disease-associated variants.
Knock-in
Knock-in of tagged AMH or AMHR2 enables tracking of ligand-receptor dynamics in live cells. Tagged knock-in of KITLG or RANKL can report pathway activity. These models are valuable for imaging and proteomic studies.
Overexpression
Overexpression of AMH or dominant-negative AMHR2 can enhance or suppress signaling, respectively. Overexpression models are useful for testing sufficiency of a candidate regulator. They can also mimic disease states such as OHSS.
How EDITGENE Supports negative regulation of anti-Mullerian hormone signaling pathway Research
Researchers studying negative regulation of anti-Mullerian hormone signaling pathway-related genes often need to determine whether a candidate gene is causally involved in attenuating AMH signaling or is merely correlated with pathway activity. CRISPR-based models provide a direct way to test causality by manipulating gene function in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of anti-Mullerian hormone signaling pathway research.
Frequently Asked Questions About negative regulation of anti-Mullerian hormone signaling pathway
What is GO:1902613?
GO:1902613 is the Gene Ontology term for negative regulation of anti-Mullerian hormone signaling pathway, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of AMH signaling.
What genes are involved in negative regulation of anti-Mullerian hormone signaling pathway?
Key genes include AMH, AMHR2, KITLG, RANKL, and SMAD effectors, as well as stromal markers like WT1.
How is AMH signaling negatively regulated?
Negative regulation can occur via dominant-negative AMHR2 splice variants, ligand sequestration, intracellular feedback, and cross-talk with other pathways.
What diseases are linked to negative regulation of AMH signaling?
Ovarian hyperstimulation syndrome, cadmium-induced granulosa cell damage, bone metabolism disorders, and autism spectrum disorder have been linked.
What is the role of AMHR2 in AMH signaling?
AMHR2 is the type 2 receptor for AMH; its splice variants can act as dominant-negative inhibitors of the pathway.
How does AMH affect ovarian follicles?
AMH inhibits primordial follicle recruitment and modulates follicle sensitivity to FSH, and its negative regulation is critical for ovarian reserve.
Does AMH signaling occur outside the ovary?
Yes, AMH signaling also occurs in osteoclasts, where it negatively regulates differentiation via RANKL suppression.
What cell models are used to study AMH signaling?
Granulosa cell lines, osteoclast precursors, and stromal fibroblast co-cultures are commonly used.
Can CRISPR be used to study negative regulation of AMH signaling?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can dissect causal roles of candidate genes.
What is the clinical relevance of AMH signaling?
AMH signaling is relevant to fertility, ovarian hyperstimulation syndrome, bone health, and neurodevelopmental sex bias.
Conclusion
GO:1902613, negative regulation of anti-Mullerian hormone signaling pathway, is a critical biological process that ensures proper control of AMH signal transduction in the ovary and beyond. Dysregulation of this process is implicated in reproductive disorders, bone metabolism, and neurodevelopmental conditions. By leveraging CRISPR-based models and multi-omics approaches, researchers can dissect the molecular players and therapeutic potential of this pathway.
References
- 1. Lv M et al.. 2025. The Effect of AMH on Folliculogenesis.. Reprod Sci 32(12):3848-3860 PMID: 40408029
- 2. Spector I et al.. 2024. Anti-Müllerian hormone signaling in the ovary involves stromal fibroblasts: a study in humans and mice provides novel insights into the role of ovarian stroma.. Hum Reprod 39(11):2551-2564 PMID: 39361580
- 3. Kim JH et al.. 2021. Anti-Müllerian Hormone Negatively Regulates Osteoclast Differentiation by Suppressing the Receptor Activator of Nuclear Factor-κB Ligand Pathway.. J Bone Metab 28(3):223-230 PMID: 34520656
- 4. Imhoff FM et al.. 2013. The type 2 anti-Müllerian hormone receptor has splice variants that are dominant-negative inhibitors.. FEBS Lett 587(12):1749-53 PMID: 23624077
- 5. Knight PG et al.. 2006. TGF-beta superfamily members and ovarian follicle development.. Reproduction 132(2):191-206 PMID: 16885529
- 6. Pankhurst MW et al.. 2012. Inhibin B and anti-Müllerian hormone/Müllerian-inhibiting substance may contribute to the male bias in autism.. Transl Psychiatry 2(8):e148 PMID: 22872163
- 7. Wang L et al.. 2015. Attenuated AMH signaling pathway plays an important role in the pathogenesis of ovarian hyperstimulation syndrome.. Am J Transl Res 7(10):1925-38 PMID: 26692936
- 8. Chen N et al.. 2020. Anti-Müllerian hormone participates in ovarian granulosa cell damage due to cadmium exposure by negatively regulating stem cell factor.. Reprod Toxicol 93:54-60 PMID: 31926278
